China NDA 2026 - Business-News-Today.com

Business-News-Today.com

Business news, market intelligence, and global industry analysis.

Business-News-Today.com

The Latest

Can fewer infusions improve adherence in Fabry disease enzyme replacement therapy?

CVS stock slips as Aetna settles Medicare Advantage diagnosis code fraud case for $117.7m

What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)

CVGI surges 54% as CVG names Zoox strategic supplier and issues $700M revenue outlook for 2026

Read More

5 minute read

Pharma Industry News

Denifanstat phase 3 acne trial success positions Ascletis for China NDA submission in 2026

Find out how Denifanstat’s Phase 3 acne trial success positions Ascletis Pharma for a 2026 China NDA submission and reshapes the acne-therapy market.

bySoujanya Ravi

October 24, 2025

web analytics